Jena University Hospital

Sirolimus-Coated Balloons Show Promise in PAD Treatment: SIRONA Trial Results

5 months ago

• The SIRONA RCT demonstrated that sirolimus-coated balloons (MagicTouch PTA) achieve similar patency and functional benefits compared to paclitaxel-coated balloons in PAD patients. • The trial, involving 482 patients, showed a primary patency of 73.8% with MagicTouch PTA versus 75% with paclitaxel DCBs, meeting the non-inferiority endpoint. • SIRONA also revealed a favorable safety profile for sirolimus-coated balloons, with no significant difference in clinically-driven target lesion revascularization at 12 months. • Concept Medical's MagicTouch PTA sirolimus-coated balloon is also under investigation in the SIRPAD trial, the world's largest RCT for PAD treatment, with over 1,250 patients enrolled.

FDA Approves Bimzelx for Psoriatic Arthritis and Spondyloarthritis; New Eczema Treatment Ebgliss

8 months ago

• The FDA has approved Bimzelx (bimekizumab-bkzx) for psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, targeting IL-17A and IL-17F to reduce inflammation. • Eli Lilly's Ebgliss (lebrikizumab-lbkz) has been approved by the FDA for moderate-to-severe eczema in patients 12 and older, showing skin clearance and itch relief in studies. • A new study indicates that osteoporosis and fracture rates have significantly decreased in rheumatoid arthritis patients over the past 24 years due to advances in treatments like biologics. • Research suggests that moderate coffee consumption (3 cups/day) may lower the risk of heart disease, stroke, and type 2 diabetes due to antioxidants and anti-inflammatory agents.

Scemblix Receives European Commission Approval for CML Treatment After TKI Failure

3 years ago

• The European Commission has approved Scemblix (asciminib) for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML-CP). • Scemblix is intended for patients previously treated with two or more tyrosine kinase inhibitors (TKIs) who have experienced resistance or intolerance. • Phase III ASCEMBL trial results showed Scemblix nearly doubled the major molecular response rate compared to bosutinib (25.5% vs. 13.2%) at 24 weeks. • Scemblix offers a novel mechanism of action as a STAMP inhibitor, targeting the ABL myristoyl pocket, providing a new therapeutic option.